DPP9-KEAP1 Mutual Inhibition: A New Axis in Redox and Inflammasome Biology

Study Background and Research Question

Inflammasomes are critical multiprotein complexes that sense cellular danger signals and activate innate immune responses, chiefly through caspase-1-mediated cytokine release and pyroptosis. The NLRP1 and CARD8 inflammasomes are regulated by tightly controlled protein–protein interactions and post-translational modifications, with dipeptidyl peptidase 9 (DPP9) acting as a key repressor of their activation. Synthetic DPP9 inhibitors have previously been shown to unlock inflammasome activity, yet the existence and identity of an endogenous, physiological DPP9 inhibitor remained unresolved. Moreover, the interplay between redox homeostasis and inflammasome activation has emerged as a research frontier, particularly in the context of neurodegenerative disease models and redox-linked cell death mechanisms. The referenced study (Tsamouri et al., 2024) addresses whether a natural DPP9-inhibiting biomolecule exists and how such inhibition might integrate with the cell’s redox sensing machinery.

Key Innovation from the Reference Study

The central advance of this research is the identification of KEAP1, a canonical redox sensor, as a direct endogenous binding partner and mutual inhibitor of DPP9. This discovery establishes a previously unrecognized molecular bridge between redox signaling and inflammasome regulation. Notably, KEAP1 binds DPP9 in an inactive conformation, stabilizing its non-native fold and thereby inhibiting its enzymatic activity. In turn, inactive DPP9 reciprocally inhibits KEAP1’s capacity to target the antioxidant transcription factor NRF2 for degradation, resulting in NRF2 stabilization and an amplified antioxidant response. This reciprocal inhibition forms a mutually regulatory complex that integrates protease activity, redox status, and innate immunity—an insight with implications for autophagy pathway research and neurodegenerative disease models.

Methods and Experimental Design Insights

The authors used a combination of biochemical, proteomic, and cellular assays to identify and characterize the DPP9-KEAP1 interaction. Co-immunoprecipitation and mass spectrometry revealed KEAP1 as a robust DPP9-binding protein in mammalian cells under specific experimental conditions that promote DPP9 unfolding—such as new protein expression and chemical denaturation. Functional assays demonstrated that the DPP9-KEAP1 interaction leads to mutual inhibition: DPP9 becomes catalytically inactive, and KEAP1 loses its ability to mediate NRF2 degradation. The team further mapped the interaction to specific conformational states of DPP9, showing that only the non-native, unfolded dimeric form of DPP9 can bind KEAP1. These approaches provided clear mechanistic evidence for the direct coupling of protease inhibition and redox sensing.

Core Findings and Why They Matter

The study’s main findings are as follows:

• KEAP1 binds and inhibits non-native DPP9, revealing an endogenous mechanism to regulate DPP9’s proteolytic activity within cells.
• DPP9 reciprocally inhibits KEAP1, preventing KEAP1 from targeting NRF2 for proteasomal degradation and thus upregulating cellular antioxidant defenses.
• This mutual inhibition links redox stress to inflammasome activation: disruptions in redox balance or proteotoxic stress may shift DPP9 into a KEAP1-binding state, triggering changes in both NRF2 and inflammasome pathways.
• Experimental induction of DPP9 conformational change (e.g., via chemical denaturants or overexpression) is sufficient to drive the DPP9-KEAP1 complex formation, although the precise physiological triggers remain to be determined.

These findings have broad implications. They advance our understanding of how cells integrate metabolic, redox, and immunological signals through direct protein–protein interactions. The DPP9-KEAP1 complex acts as a molecular switch, modulating both inflammasome repression and antioxidant responses—a key consideration for researchers investigating caspase activation assays, autophagy pathway research, and the pathogenesis of neurodegenerative diseases.

Comparison with Existing Internal Articles

This new evidence expands the landscape of redox-inflammasome coupling beyond previously characterized mechanisms. Internal resources such as "Rotenone and Redox Stress: Translating Mitochondrial Insights" have highlighted how mitochondrial Complex I inhibition with rotenone can induce redox stress, mitochondrial dysfunction, and downstream inflammasome activation. The present study complements these insights by detailing a direct molecular link—DPP9-KEAP1 mutual inhibition—that could underlie or amplify such stress responses observed after rotenone exposure.

Other internal analyses, like "Rotenone as a Strategic Probe", have emphasized the importance of redox and post-translational regulation in neurodegeneration models. The new data on DPP9-KEAP1 provide a mechanistic rationale for how redox perturbations—whether from mitochondrial Complex I inhibitors, environmental toxins, or disease states—might be transduced into specific inflammasome and antioxidant responses. This conceptual advance is highly relevant for researchers employing rotenone as a mitochondrial dysfunction inducer in Parkinson's disease models or in studies of apoptosis and autophagy pathways in SH-SY5Y cells, as discussed in further internal articles.

Limitations and Transferability

While the discovery of a DPP9-KEAP1 mutual inhibition complex is significant, several limitations remain. The study identifies experimental conditions—such as protein overexpression and chemical denaturation—that promote DPP9 unfolding and KEAP1 binding. However, the endogenous stressors or physiological signals that elicit this conformational transition in vivo are not fully elucidated. As such, the direct relevance to disease contexts (e.g., neurodegeneration, chronic inflammation) will require further investigation. Additionally, the downstream effects on NLRP1 and CARD8 inflammasome activation, while mechanistically plausible, are inferred rather than directly demonstrated in this work. Extrapolation to complex models—such as in vivo Parkinson's disease research—should thus be performed with caution and ideally with complementary assays (e.g., caspase activation, ROS measurement, autophagy markers).

Protocol Parameters

• Complex I inhibition (redox stress induction): Rotenone at 50 nM for 24–48 hours in differentiated SH-SY5Y cells effectively induces mitochondrial dysfunction and downstream stress pathways, as described in internal resources.
• Inflammasome activation (NLRP1/CARD8): DPP9 inhibition (using synthetic inhibitors or genetic manipulation) can be combined with redox stressors to study mutually reinforcing effects on inflammasome assembly and caspase-1 activation.
• NRF2 stabilization assay: Monitor NRF2 levels and KEAP1-DPP9 binding via immunoprecipitation under redox stress or proteotoxic challenge.
• Protein–protein interaction mapping: Employ co-immunoprecipitation and mass spectrometry to confirm KEAP1-DPP9 complex formation in relevant cell models.

Why this cross-domain matters, maturity, and limitations

The intersection of redox biology, mitochondrial dysfunction, and innate immunity is particularly important for neurodegenerative disease research. The DPP9-KEAP1 axis provides a plausible mechanistic link between environmental/mitochondrial stressors (e.g., rotenone exposure) and inflammasome-driven inflammation. However, as the physiological triggers for DPP9 unfolding remain to be clarified, applying these findings in vivo or in human disease models should be done with careful validation. The mutual inhibition paradigm may also inform therapeutic strategies targeting either redox homeostasis or inflammasome regulation, but translational maturity is at an early stage.

Research Support Resources

To experimentally dissect the interplay between redox stress, mitochondrial dysfunction, and inflammasome pathways, researchers can utilize Rotenone (SKU B5462), a well-characterized mitochondrial Complex I inhibitor supplied by APExBIO. Rotenone enables precise induction of mitochondrial stress and ROS generation, providing a solid platform for modeling the cellular conditions relevant to DPP9-KEAP1 interactions, caspase activation, and autophagy pathway research. For detailed protocols and advanced guidance on integrating rotenone into mitochondrial and neuroinflammatory workflows, see the referenced internal articles above. Product specifications and handling recommendations are available from the manufacturer.